down arrow

Lupin

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE326A01037
  • NSEID: LUPIN
  • BSEID: 500257
INR
1,980.00
58.7 (3.06%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 6.22 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Divi's Lab.
Abbott India
Cipla
Lupin
Zydus Lifesci.
Alkem Lab
Sun Pharma.Inds.
Torrent Pharma
Glaxosmi. Pharma
Aurobindo Pharma
Mankind Pharma
Why is Lupin Ltd. ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Healthy long term growth as Operating profit has grown by an annual rate 16.86%
3
The company has declared Positive results for the last 9 consecutive quarters
  • ROCE(HY) Highest at 18.68%
  • OPERATING PROFIT TO INTEREST(Q) Highest at 20.27 times
  • NET SALES(Q) Highest at Rs 5,767.71 cr
4
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 04-Apr-25
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
5
With ROE of 16.8, it has a Attractive valuation with a 5.6 Price to Book Value
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 23.38%, its profits have risen by 60.2% ; the PEG ratio of the company is 0.5
6
High Institutional Holdings at 46.79%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating Performance
  • Even though the market (BSE 500) has generated negative returns of -1.01% in the last 1 year, the stock has been able to generate 23.38% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Lupin should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Lupin for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Lupin
23.33%
0.79
29.41%
SENSEX
0.45%
0.03
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
6.14%
EBIT Growth (5y)
16.86%
EBIT to Interest (avg)
4.74
Debt to EBITDA (avg)
3.17
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.01
Tax Ratio
20.04%
Dividend Payout Ratio
19.04%
Pledged Shares
0
Institutional Holding
46.79%
ROCE (avg)
7.82%
ROE (avg)
5.64%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
31
Industry P/E
33
Price to Book Value
5.61
EV to EBIT
23.85
EV to EBITDA
17.89
EV to Capital Employed
5.46
EV to Sales
4.01
PEG Ratio
0.51
Dividend Yield
0.42%
ROCE (Latest)
21.01%
ROE (Latest)
16.79%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
ROCE(HY)

Highest at 18.68%

OPERATING PROFIT TO INTEREST(Q)

Highest at 20.27 times

NET SALES(Q)

Highest at Rs 5,767.71 cr

PBDIT(Q)

Highest at Rs 1,355.90 cr.

PBT LESS OI(Q)

At Rs 1,017.56 cr has Grown at 30.7% (vs previous 4Q average

PAT(Q)

At Rs 855.16 cr has Grown at 30.2% (vs previous 4Q average

EPS(Q)

Highest at Rs 18.74

-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Lupin
Operating Profit to Interest - Quarterly
Highest at 20.27 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales - Quarterly
Highest at Rs 5,767.71 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 1,355.90 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1,017.56 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1,017.56 cr has Grown at 30.7% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 778.25 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 855.16 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 855.16 cr has Grown at 30.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 656.62 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 18.74
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)